Skip to content

Study · Not a test of the peptide alone · 2025

2 results

New onset diabetic retinopathy with glucagon-like peptide-1 receptor agonists: A case report.

Ko J, Jahromi Y

Journal of the American Pharmacists Association : JAPhA2 Jul 2025Cited by 3 (Europe PMC)

PMID40609682 (opens in a new tab)DOI10.1016/j.japh.2025.102475 (opens in a new tab)PepBankPUB-40609682
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

  1. 01HumanNot a test of Semaglutide aloneCase report or seriesSafety outcome

    In one woman with type 2 diabetes who had taken several GLP-1 receptor agonists in sequence, diabetic macular edema was detected 2 months after a switch to subcutaneous semaglutide.

    In plain wordsIn one woman who had used several GLP-1 drugs in turn, eye swelling was found 2 months after starting injected semaglutide.

    Peptide
    Semaglutide
    Outcome
    IncreaseDiabetic macular edema after subcutaneous semaglutide
    Study

    n = 1

    Outcome group
    Adverse events · Eye

    Source sentences

    Summary
    A 43-year-old female with T2D and class II obesity was diagnosed with mild nonproliferative DR after taking various GLP1-RA therapy (ie, exenatide ER and dulaglutide) and maintaining glycemic control for 19 months.
    1 context sentence
    Summary · context
    The patient was later transitioned to subcutaneous semaglutide for additional weight loss, and diabetic macular edema was detected in the right eye 2 months after.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  2. 02HumanNot a test of Semaglutide aloneCase report or seriesEfficacy outcome

    In one woman with type 2 diabetes and retinopathy, retinopathy improved and macular edema largely resolved 8 months after a switch from subcutaneous to oral semaglutide, after earlier GLP-1 receptor agonist drugs.

    In plain wordsIn one woman, her eye disease improved 8 months after switching from injected to oral semaglutide. This one case cannot show cause.

    Peptide
    Semaglutide
    Outcome
    DecreaseDiabetic retinopathy and macular edema after switch to oral semaglutide
    Study

    n = 1

    Outcome group
    Vision and retina · Eye

    Source sentences

    Summary
    Due to a potentially lower risk of DR complications, treatment was promptly switched to oral semaglutide. The patient's eye exam revealed that her DR improved and diabetic macular edema had significantly resolved 8 months after switching therapy.
    1 context sentence
    Summary · context
    A 43-year-old female with T2D and class II obesity was diagnosed with mild nonproliferative DR after taking various GLP1-RA therapy (ie, exenatide ER and dulaglutide) and maintaining glycemic control for 19 months.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.